Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

Company profile

Ticker

NAVB

Exchange

NYSE

Website

www.navidea.com

CEO

Jed Latkin

Incorporated

Delaware

Location

Ohio

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • QuidelOrtho • Meridian Bioscience • Celldex Therapeutics • Achieve Life Sciences ...

Former names

NEOPROBE CORP

SEC CIK

0000810509

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Navidea Biopharmaceuticals Europe Limited • Navidea Biopharmaceuticals Limited • Macrophage Therapeutics, Inc. ...

IRS number

311080091

NAVB stock data

1M 1Y 5Y

News

From Benzinga Pro

Navidea Biopharmaceutical Q2 EPS $(0.10) Down From $(0.09) YoY, Sales $57.00K Down From $261.05K YoY

15 Aug 22

Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.10) per share. This is a 11.11 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $57.00

Navidea Biopharmaceuticals Announces Publication Of Study Examining Use Of Tc99m Tilmanocept For Lymphatic Mapping And Sentinel Lymph Node Biopsy In Melanoma And Oral Cancer In Australia

1 Aug 22

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the

Navidea Biopharmaceuticals Highlights Publication Of Study Examining Tc99m Tilmanocept Imaging Of Arterial Inflammation In People With HIV

25 Jul 22

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the

Press releases

From Benzinga Pro

Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

15 Aug 22

Conference Call to be Scheduled at a Later Date Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and

Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

4 Aug 22

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the subscription period

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

1 Aug 22

Navidea Biopharmaceuticals Reminds Investors of Today's Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

1 Aug 22

Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

25 Jul 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

15 Aug 22

16 Aug 22

31 Dec 22

Financial summary

Financial statements Chart NAVB financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	328.01K	328.01K	328.01K	328.01K	328.01K	328.01K
Cash burn (monthly)	296.37K	565.51K	974.2K	997.99K	713.1K	786.35K
Cash used (since last report)	465.35K	887.95K	1.53M	1.57M	1.12M	1.23M
Cash remaining	-137.34K	-559.94K	-1.2M	-1.24M	-791.69K	-906.71K
Runway (months of cash)	-0.5	-1.0	-1.2	-1.2	-1.1	-1.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

NAVB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
31 Jul 22	Amit Bhalla	Common Stock	Grant	Acquire A	No	No	2,500	63,068
31 Jul 22	Alexander L Cappello	Common Stock	Grant	Acquire A	No	No	2,500	58,977
31 Jul 22	Scott John K Jr.	Common Stock	Grant	Acquire A	No	No	2,500	8,100,895
31 Jul 22	Malcolm G Witter	Common Stock	Grant	Acquire A	No	No	2,500	156,388
30 Jun 22	Amit Bhalla	Common Stock	Grant	Acquire A	No	No	2,500	60,568

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

NAVB institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: API, appraisal, arrival, bisphosphonate, clawback, destination, Dis, ingredient, installment, Jul, Junior, NDA, NN, online, point, satisfaction, shipment, shipping, sponte, sua, Summit, Tc, technetium, unregistered, warrant, wire

Removed: Cerveau, exclusive, inception, relating, Singapore

From filing 10-Q 2022 Q2

Financial reports

View all